Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 42
- Registration Number
- NCT04774718
- Locations
- 🇮🇹
Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS, Genova, Liguria, Italy
🇮🇹Istituto Nazionale Tumori di Milano; S.C. Oncologia Pediatrica, Milano, Lombardia, Italy
🇮🇹Dipartimento di Scienze Pediatriche Adolescenza; Osp. Infantile Regina Margherita, Torino, Piemonte, Italy
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 554
- Registration Number
- NCT04770896
- Locations
- 🇦🇹
Medizinische Universität Innsbruck; Universitätsklinik für Innere Medizin I, Innsbruck, Austria
🇦🇹Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU, Salzburg, Austria
🇦🇹Universitätsklinikum St. Pölten; Innere Medizin 2, St. Pölten, Austria
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 800
- Registration Number
- NCT04764188
- Locations
- 🇨🇴
Instituto Cancerología Medellin, Medellin, Colombia
🇦🇷Clinica Adventista Belgrano; Oncology, Ciudad Autonoma Buenos Aires, Argentina
🇦🇺Lifehouse, Camperdown, New South Wales, Australia
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT04760288
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocio, Sevilla, Spain
A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device.
- Conditions
- Interventions
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 71
- Registration Number
- NCT04751162
- Locations
- 🇪🇸
Hospital La Paz, Madrid, Spain
🇪🇸Hospital Universitari de Girona Dr Josep Trueta; Departamento de Oncologia Medica, Girona, Spain
🇪🇸Fundacion Hospital de Alcorcon, Alcorcon, Madrid, Spain
A Study of Trastuzumab Emtansine in Combination with Atezolizumab or Placebo As a Treatment for Participants with Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT04740918
- Locations
- 🇺🇸
Emad Ibrahim, Md, Inc, Redlands, California, United States
🇦🇺Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia
🇦🇺Royal North Shore Hospital; Oncology, St. Leonards, New South Wales, Australia
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 553
- Registration Number
- NCT04740905
- Locations
- 🇵🇱
Gabinet Okulistyczny Prof Edward Wylegala, Katowice, Poland
🇺🇸Cumberland Valley Retina PC, Hagerstown, Maryland, United States
🇦🇺The Lions Eye Institute, Nedlands, Western Australia, Australia
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
- Conditions
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 729
- Registration Number
- NCT04740931
- Locations
- 🇺🇸
Fort Lauderdale Eye Institute, Plantation, Florida, United States
🇺🇸Assoc Retinal Consultants PC, Royal Oak, Michigan, United States
🇺🇸Midwest Vision Research Foundation, Chesterfield, Missouri, United States
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT04732286
- Locations
- 🇪🇸
Complejo Hospitalario Torrecardenas; Servicio de Hepatologia, Almeria, Spain
🇪🇸Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia, Sevilla, Spain
🇪🇸Hospital Universitario de Torrejon; Servicio de Oncología, Torrejón de Ardoz, Madrid, Spain
Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT04729309
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom